In-vitro Effects of Vancomycin, Rifampicin, and Fusidic Acid, Alone and in Combination, Against Methicillin-resistant Staphylococcus Aureus
Overview
Authors
Affiliations
Minimal inhibitory and minimal bactericidal concentrations were determined for eighteen methicillin-resistant Staphylococcus aureus isolates, the majority also resistant to gentamicin, obtained from the blood of bacteraemic patients. Fifty per cent of organisms had a greater than four-fold difference in M.I.C. and M.B.C. for vancomycin, 83% for rifampicin, and 89% for fusidic acid. In-vitro effects of two-drug combinations of vancomycin, rifampicin, and fusidic acid demonstrated neither synergy nor antagonism when measured by a checkerboard dilution technique. The relevance of these findings to choice of therapy of serious infection due to methicillin-gentamicin resistant Staph. aureus is yet to be determined.
Amycolatopsis sp. nov., a Halotolerant Actinobacterium, Produces New Secondary Metabolites.
Li R, Wang M, Ren Z, Ji Y, Yin M, Zhou H Front Microbiol. 2021; 12:743116.
PMID: 34938275 PMC: 8685341. DOI: 10.3389/fmicb.2021.743116.
Xu L, Huang H, Wei W, Zhong Y, Tang B, Yuan H BMC Genomics. 2014; 15:363.
PMID: 24884615 PMC: 4048454. DOI: 10.1186/1471-2164-15-363.
Kwong J, Chua K, Charles P Curr Infect Dis Rep. 2012; 14(3):330-8.
PMID: 22430229 DOI: 10.1007/s11908-012-0254-8.
Hodges T, Slattery M, Olson J Mar Biotechnol (NY). 2011; 14(3):270-80.
PMID: 22002467 DOI: 10.1007/s10126-011-9410-7.
Rifampin combination therapy for nonmycobacterial infections.
Forrest G, Tamura K Clin Microbiol Rev. 2010; 23(1):14-34.
PMID: 20065324 PMC: 2806656. DOI: 10.1128/CMR.00034-09.